Candel Therapeutics, Inc. (CADL) · Aug 13, 2026 · Earnings

The pipeline held steady—but the quarterly loss was far worse than expected

Miss — GAAP EPS $(0.52) vs approximately $(0.23) consensus

Candel kept its Q4 BLA and Q1 2028 cash-runway plans intact, but a warrant-driven loss missed consensus by a wide margin.

The earnings headline was a clear miss. Candel reported a GAAP loss of $0.52 per share, versus a published consensus of approximately $0.23 loss per share, making the quarter materially worse than expected. The miss was driven largely by a $12.3 million unfavorable change in warrant-liability fair value, so it was primarily non-cash rather than a direct deterioration in clinical execution (Consolidated Statements of Operations).

MetricQ2 2026Q2 2025 / comparisonRead-through
Research and development expense$19.8M$7.0MHigher trial and manufacturing spending (Consolidated Statements of Operations)
General and administrative expense$6.9M$4.2MHigher commercial-readiness costs (Consolidated Statements of Operations)
Net loss$(38.9)M$(4.8)MWarrant revaluation amplified the loss (Consolidated Statements of Operations)
Basic EPS$(0.52)$(0.09)Below approximately $(0.23) consensus (Consolidated Statements of Operations)
Cash and equivalents$201.6M$119.7M at Dec. 31, 2025Runway projected into Q1 2028 (Balance Sheet Data; Cash Position)

The clinical and regulatory story was mostly confirmation, not a fresh surprise. The 39% improvement in prostate cancer-specific disease-free survival came from data initially announced in December 2024 and extended follow-up presented in May 2026; publication in The Lancet Oncology adds validation but does not materially change the underlying evidence (Aglatimagene—Prostate Cancer). The first AURORA site activation, the commercial-chief appointment, and the Q4 2026 BLA target were also already disclosed or previously anticipated (Recent Corporate Events; Anticipated Milestones).

The operating picture is advancing, but at a higher cash-burn rate. R&D expense nearly tripled year over year as Candel funds manufacturing validation, the prostate BLA effort, and the new NSCLC phase 3 trial, while G&A rose with commercial preparation (Consolidated Statements of Operations). The company still says $201.6 million of cash funds its current plan into Q1 2028, including potential 2027 launch preparation, but that runway depends on the stated operating plan and does not remove regulatory or execution risk (Cash Position; Forward-Looking Statements).

Net read: a financial miss against a largely unchanged development narrative. The quarter did not weaken the prostate program's disclosed clinical results or delay the planned BLA, but it offered little new upside because the major milestones were already known. Against expectations, the warrant-driven EPS shortfall outweighs the steady pipeline update, producing a slight negative read.

What to watch next

BLA submission for aglatimagene, Q4 2026

Original filing on SEC EDGAR

More Candel Therapeutics, Inc. news

The pipeline held steady—but the quarterly loss was far worse than expected | CADL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.